LAVA Therapeutics (LVTX)
(Delayed Data from NSDQ)
$1.59 USD
-0.06 (-3.64%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $1.59 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.59 USD
-0.06 (-3.64%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $1.59 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Zacks News
All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy
by Zacks Equity Research
LAVA Therapeutics (LVTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -125% and 5.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 0% and 105.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aravive (ARAV) delivered earnings and revenue surprises of 60% and 27.40%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Evogene (EVGN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Evogene (EVGN) delivered earnings and revenue surprises of 10.53% and 15.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall
by Zacks Equity Research
Lava (LVTX) falls 10% due to its decision to discontinue the study on LAVA-051, which is being evaluated for multiple hematological tumors. The company shifts focus to LAVA-1207 in the prostate cancer study.
LAVA (LVTX) Up on J&J's (JNJ) Cancer Study Candidate Selection
by Zacks Equity Research
LAVA's (LVTX) shares soar as partner J&J (JNJ) selects a lead candidate for development in clinical studies for cancer.
Is a Beat Likely for Cooper Companies (COO) in Q2 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.
Fortress Biotech (FBIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -10.53% and 23.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Geron (GERN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of 22.22% and 85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -37.50% and 59.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 35.71% and 30.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 14.29% and 4.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Can LAVA Therapeutics N.V. (LVTX) Climb 198% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for LAVA Therapeutics N.V. (LVTX) points to a 197.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
LAVA Therapeutics N.V. (LVTX) Q3 Earnings Surpass Estimates
by Zacks Equity Research
LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 157.14% and 38.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Will LAVA Therapeutics N.V. (LVTX) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
LAVA Therapeutics N.V. (LVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of 1.15% and 131.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 0% and 388.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cytek Biosciences, Inc. (CTKB) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 100% and 6.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Insmed (INSM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -22.47% and 0.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Seagen's (SGEN) Portfolio of Drugs Help Combat Rivalry?
by Zacks Equity Research
Seagen (SGEN) expects its portfolio of marketed drugs, which are approved for various cancer indications, to generate incremental sales and combat stiff competition.
Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223
by Zacks Equity Research
Seagen (SGEN) signs an exclusive agreement with LAVA Therapeutics to develop and commercialize the latter's preclinical asset, LAVA-1223, targeting EGFR-expressing solid tumors.
LAVA Therapeutics N.V. (LVTX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
LAVA Therapeutics N.V. (LVTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 49.18% and 53.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Fstar Therapeutics, Inc. (FSTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fstar Therapeutics, Inc. (FSTX) delivered earnings and revenue surprises of -41.94% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?